ストックスクリーナーアプリを入手
1.14
3.64%
0.04
アフターアワーズ：
1.16
0.02
+1.75%
前日終値:
$1.10
開ける：
$1.12
24時間の取引高:
677.30K
Relative Volume:
0.75
時価総額：
$48.57M
収益：
-
当期純損益:
$-40.92M
株価収益率:
-0.6641
EPS:
-1.7167
ネットキャッシュフロー:
$-26.53M
1週間 パフォーマンス:
+1.79%
1か月 パフォーマンス:
-36.67%
6か月 パフォーマンス:
-53.85%
1年 パフォーマンス:
-51.49%
1日の値動き範囲:
$1.09
$1.16
1週間の範囲:
$1.04
$1.17
52週間の値動き範囲:
$1.04
$5.50
Annovis Bio Inc Stock (ANVS) Company Profile
名前
Annovis Bio Inc
セクター
電話
484-875-3192
住所
101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA
Compare ANVS vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ANVS
Annovis Bio Inc
|
1.14 | 47.72M | 0 | -40.92M | -26.53M | -1.7167 |
VRTX
Vertex Pharmaceuticals Inc
|
508.34 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
784.85 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
990.32 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
154.04 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
190.95 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-10 | ダウングレード | D. Boral Capital | Buy → Hold |
| 2024-10-25 | アップグレード | Maxim Group | Hold → Buy |
| 2023-12-29 | 開始されました | Canaccord Genuity | Buy |
| 2021-07-07 | 繰り返されました | Maxim Group | Buy |
Annovis Bio Inc (ANVS) 最新ニュース
Annovis Bio announces special shareholder meeting - Bitget
Annovis Bio (ANVS) Loses 26.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Annovis Bio stock reacts to webinar plan and steep discount to analyst targets - ad-hoc-news.de
Annovis Bio Stock Price Forecast. Should You Buy ANVS? - StockInvest.us
Roth MKM Maintains Annovis Bio(ANVS.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Annovis Bio Targets March 2027 Alzheimer’s Readout, Prepares Rolling NDA - TradingView
ANVS: Top-line phase III Alzheimer's data expected in March, with NDA filing and funding plans in place - TradingView
Annovis Bio (ANVS) Edges Higher, Holding Key Support at $1.65Momentum Breakout Ideas - vinanet.vn
Annovis Bio Drops Nearly 5% to $1.72 as Biotech Volatility ResurfacesBearish Pattern Stocks - vinanet.vn
ANVS Q2 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost DisciplineProfit Announcement - vinanet.vn
Roth MKM Maintains Annovis Bio(ANVS.US) With Buy Rating, Cuts Target Price to $7 - Moomoo
Annovis to Host Corporate Update Webinar on September 2, 2026 - Yahoo Finance
Annovis (ANVS) Results Breakdown: Profit Per Share Falls Below Its Benchmark in Latest Trading; Closing Reaction - vinanet.vn
Analysts Offer Insights on Healthcare Companies: Annovis Bio (ANVS) and Acurx Pharmaceuticals (ACXP) - The Globe and Mail
CCORF Maintains Annovis Bio(ANVS.US) With Buy Rating, Maintains Target Price $17 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Annovis Bio (NYSE:ANVS) Given "Buy" Rating at Canaccord Genuity Group - MarketBeat
Annovis Bio stock price target reiterated at $17 by Canaccord - Investing.com
Annovis Bio Inc (ANVS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Certain Stock Options of Annovis Bio, Inc. are subject to a Lock-Up Agreement Ending on 17-AUG-2026. - marketscreener.com
Annovis Bio (ANVS) Advances 3.35% as Shares Test Key Resistance Near $1.94Volume Profile - vinanet.vn
Annovis Bio (NYSE:ANVS) Posts Quarterly Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat
Annovis Bio (ANVS) posts $32.4M loss and warns on going-concern risk - Stock Titan
ANVS: Net loss rose sharply as clinical trial costs surged, with cash runway only through Q4 2026 - TradingView
Annovis Bio | 10-Q: Q2 2026 Earnings Report - Moomoo
ANVS: Alzheimer's Phase 3 trial fully enrolled; R&D costs and net loss per share increased year-over-year - tradingview.com
Annovis Reports $14.8 Million Q2 Loss as Phase 3 AD Trial Fully Enrolls - Quiver Quantitative
Highbridge Capital (ANVS) discloses 6.1% Annovis Bio stake tied to 2.78M warrant shares - Stock Titan
Annovis Bio | SCHEDULE 13G: Others - Moomoo
Annovis Bio Sees Unusually Large Options Volume (NYSE:ANVS) - MarketBeat
Annovis Bio Q2 EPS of $(0.40) beats $(0.45) estimate - scanx.trade
Annovis Bio Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results - The Manila Times
ANNOVIS BIO Q2 EPS USD -0.4 - Moomoo
Press Release: Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results - Moomoo
Annovis Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Empery Asset Management, LP's Annovis Bio Inc(ANVS) Holding History - GuruFocus
Annovis Bio (ANVS) Holds Ground at $1.79, Testing Critical Support in a Cautious Biotech MarketOn Balance Volume - vinanet.vn
Annovis Bio, Inc. (ANVS) options chain - Yahoo Finance Singapore
Annovis Bio (ANVS) Edges Lower But Holds Above Key Support at $1.78Overvalued Signals - vinanet.vn
Annovis Bio Inc (ANVS) Stock News Today - TradingKey
Annovis Bio Inc expected to post a loss of 45 cents a shareEarnings Preview - TradingView
Annovis Bio (ANVS) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
Annovis Bio, Inc. (NYSE:ANVS) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Annovis Bio (ANVS) Rallies 5% as Stock Approaches Key ResistanceDeath Cross - vinanet.vn
Annovis Bio (ANVS): Empery Asset Management discloses 5.64% beneficial stake - Stock Titan
ANVS|Annovis Bio Inc|Price:1.665|Chg%:+0.005 - TradingKey
Annovis Bio Inc (ANVS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Annovis Bio Inc (ANVS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Annovis Bio Inc (ANVS) Institutional Confidence - TradingKey
Annovis Bio Inc (ANVS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Annovis Bio Inc (ANVS) 財務データ
収益
当期純利益
現金流量
EPS
0.88%
大文字化:
|
ボリューム (24 時間):